Trial Profile
Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 13 Dec 2022 Results assessing the molecular variants associated with resistance to a quadruplet treatment combination in newly diagnosed multiple myeloma treated with targeted-immunotherapy, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 14 Dec 2021 Plasma cells from bone marrow (BM) samples from patients from this and another study (NCT03290950) were used to predict genomic and immune signatures, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 10 Feb 2021 Status changed from active, no longer recruiting to completed.